Next generation proteomic cancer detection via liquid biopsy

Tissue biopsy

Stacks Image 33
  • Invasive with unwelcome side effects: 20% experience a biopsy-related adverse event including haemorrhage, pneumothorax and respiratory failure
  • Time consuming: 15 to 80 days including time to acquire sample test results
  • Expensive: average cost up to $20,000
  • Does not adapt to patients' specificities: differences in molecular profile by location of the biopsy

Liquid biopsy

Stacks Image 36
  • Safe, non-invasive approach 
  • Lower total test cost: do not require a trained professional
  • Quicker turnaround time: up to a few days with potential to decrease to a few minutes
  • Real-time monitoring: provide molecular insight into drug-resistant patients
  • Capture tumour heterogeneity
  • Predict recurrence: detection of cancer relapse during remission can offer “quantitative peace of mind" for cancer survivors
  • Enable broad-based screening: earlier diagnosis is key

Tissue biopsy

Tissue biopsy

Stacks Image 74
  • Invasive with unwelcome side effects: 20% experience a biopsy-related adverse event including haemorrhage, pneumothorax and respiratory failure
  • Time consuming: 15 to 80 days including time to acquire sample test results
  • Expensive: average cost up to $20,000
  • Does not adapt to patients' specificities: differences in molecular profile by location of the biopsy
  • Invasive with unwelcome side effects: 20% experience a biopsy-related adverse event including haemorrhage, pneumothorax and respiratory failure
  • Time consuming: 15 to 80 days including time to acquire sample test results
  • Expensive: average cost up to $20,000
  • Does not adapt to patients' specificities: differences in molecular profile by location of the biopsy

Liquid biopsy

Liquid biopsy

Stacks Image 77
  • Safe, non-invasive approach 
  • Lower total test cost: do not require a trained professional
  • Quicker turnaround time: up to a few days with potential to decrease to a few minutes
  • Real-time monitoring: provide molecular insight into drug-resistant patients
  • Capture tumour heterogeneity
  • Predict recurrence: detection of cancer relapse during remission can offer “quantitative peace of mind" for cancer survivors
  • Enable broad-based screening: earlier diagnosis is key
  • Safe, non-invasive approach 
  • Lower total test cost: do not require a trained professional
  • Quicker turnaround time: up to a few days with potential to decrease to a few minutes
  • Real-time monitoring: provide molecular insight into drug-resistant patients
  • Capture tumour heterogeneity
  • Predict recurrence: detection of cancer relapse during remission can offer “quantitative peace of mind" for cancer survivors
  • Enable broad-based screening: earlier diagnosis is key

Device mechanism

Device mechanism

We believe that our nanosensor prototype is one of the best positioned to enable liquid biopsy at the point-of-care on an industrial scale. Thanks to our nanotechnology platform, we aim at creating hundreds of thousands of biosensors within one nanochip (~1cm2) and, in combination with relevant bioalgorithm, we could deliver a cheap multiplex protein biomarker cancer panel solution.  
Our unique ability to design electrodes with specific geometry, interacting with single proteins at the nano-level (10
-9 meter), shall provide results with very high sensitivity and specificity while proteins' variability will be minimized through statistical tools.
We believe that our nanosensor prototype is one of the best positioned to enable liquid biopsy at the point-of-care on an industrial scale. Thanks to our nanotechnology platform, we aim at creating hundreds of thousands of biosensors within one nanochip (~1cm2) and, in combination with relevant bioalgorithm, we could deliver a cheap multiplex protein biomarker cancer panel solution.  
Our unique ability to design electrodes with specific geometry, interacting with single proteins at the nano-level (10
-9 meter), shall provide results with very high sensitivity and specificity while proteins' variability will be minimized through statistical tools.
Stacks Image 41
Stacks Image 49
Stacks Image 51
Stacks Image 53
We provide a competitive and differentiated proposal with much larger predictive power than deep gene sequencing technologies as we rely on large panels of approved protein biomarkers. The device is differentiated from CTC (Circulating tumors cells), vesicles or nuclear acids detection mechanisms as we deal directly with the functional players that drive both normal and disease physiology.
We are currently collaborating with the University of Cambridge on the development of a prototype and are welcoming your feedbacks on how we could best adapt it to your needs.
We provide a competitive and differentiated proposal with much larger predictive power than deep gene sequencing technologies as we rely on large panels of approved protein biomarkers. The device is differentiated from CTC (Circulating tumors cells), vesicles or nuclear acids detection mechanisms as we deal directly with the functional players that drive both normal and disease physiology.
We are currently collaborating with the University of Cambridge on the development of a prototype and are welcoming your feedbacks on how we could best adapt it to your needs.